Tissue Regenix Group PLC Pan European distribution agreement with Arthrex (1208H)

TIDMTRX

RNS Number : 1208H

Tissue Regenix Group PLC

13 November 2018

Tissue Regenix Group plc

Pan European distribution agreement with Arthrex, Inc.

Leeds, 13 November 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that its subsidiary 'CellRight Technologies', has entered into an agreement, effective immediately, allowing Arthrex, Inc. to distribute its proprietary 'BioRinse' bone portfolio throughout Europe, with the initial focus on the UK.

This new agreement builds on the existing US relationship signed in March 2018 and is a direct result of the collaborative work that Arthrex and Tissue Regenix have been undertaking to evaluate additional business opportunities.

Steve Couldwell, CEO, Tissue Regenix Group plc commented: "I am delighted to announce an extension to our collaboration with Arthrex. Since signing the US distribution agreement in March we have continued to build a strong alliance, identifying areas where we can work together and leverage the expertise of both companies. This European agreement allows us to exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex' expansive distribution network, another significant milestone towards our vision of building a leading force in regenerative medicine."

For more Information:

 
 Tissue Regenix Group plc                   Tel: 0330 430 3073 / 07920 272 
  Caitlin Pearson, Head of Communications    441 
-----------------------------------------  ------------------------------- 
 
 Jefferies International Ltd                Tel: 0207 029 8000 
  Simon Hardy / Christopher Binks 
-----------------------------------------  ------------------------------- 
 
 FTI Consulting                             Tel: 0203 727 1000 
  Brett Pollard / Mo Noonan/ Mary Whittow 
=========================================  ===============================

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CNTGGGMCGUPRPGP

(END) Dow Jones Newswires

November 13, 2018 02:01 ET (07:01 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024